Evidence map›Paper›PMID 30929061›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2020

Longitudinal multi-level biomarker analysis of BDNF in major depression and bipolar disorder.

Katrin Schröter, Murielle Brum, Nathalie Brunkhorst-Kanaan, Franziska Tole, Christiane Ziegler, Katharina Domschke, Andreas Reif, Sarah Kittel-Schneider

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Biomedicines · 2023
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katrin SchröterDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany.
Murielle BrumDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany.
Nathalie Brunkhorst-KanaanDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany.
Franziska ToleDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany.
Christiane ZieglerDepartment of Psychiatry and Psychotherapy, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Katharina DomschkeDepartment of Psychiatry and Psychotherapy, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Andreas ReifDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany.
Sarah Kittel-SchneiderDepartment of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany. Sarah.Kittel-Schneider@kgu.de.ORCID http://orcid.org/0000-0003-3057-6150
Goethe University Frankfurt · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preliminary evidence suggests that BDNF (brain derived neurotrophic factor) rs6265 genetic polymorphism, BDNF gene promotor methylation and BDNF serum levels might play an important role in the pathogenesis of affective disorders. As studies testing the BDNF system across molecular levels are sparse, this study aimed at investigating the BDNF val66met genotype, BDNF DNA methylation changes and peripheral BDNF serum levels in acute and remitted phases of MDD (major depressive disorder) and BD (bipolar disorder) and healthy controls. We found a significant difference of methylation levels at CpG site 1-1-1 and 3-1-1 between MDD and healthy controls (p < 0.003) with MDD patients showing significantly higher methylation levels. CpG 5-2-1 revealed a statistically significant difference between MDD and healthy controls and MDD and BD (p = 0.00003). Similar to the results of the methylation analysis a significant difference between MDD and healthy controls was found in BDNF serum levels (p = 0.002) with significantly lower BDNF serum levels in MDD compared to healthy controls. A difference between the samples from admission and discharge from hospital of both BDNF gene methylation and serum levels could not be detected in the present study and no influence of the BDNF val66met genotype on neither methylation nor BDNF serum level.

Indexed as

DNA MethylationAdultBiomarkersBipolar DisorderBrain-Derived Neurotrophic FactorCpG IslandsFemaleHumansLongitudinal StudiesMajor Depressive DisorderMaleMiddle AgedPatient AdmissionPatient DischargePromoter Regions, GeneticRemission InductionBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorBDNFBipolar disorderFluid biomarkerMajor depressionRisk gene

Identifiers

PMID30929061
OpenAlexW2933196072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.